BioMarin Pharmaceutical (BMRN) : Traders are bullish on BioMarin Pharmaceutical (BMRN) as it has outperformed the S&P 500 by a wide margin of 18.2% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 6.31%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 6.24% in the last 1 week, and is up 22.17% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 11.15% and the 50-Day Moving Average is 15.12%. BioMarin Pharmaceutical Inc. is up 17.41% in the last 3-month period. Year-to-Date the stock performance stands at -5.1%.
BioMarin Pharmaceutical (NASDAQ:BMRN): stock turned positive on Friday. Though the stock opened at $98.18, the bulls momentum made the stock top out at $99.62 level for the day. The stock recorded a low of $96.17 and closed the trading day at $99.42, in the green by 1.24%. The total traded volume for the day was 1,448,311. The stock had closed at $98.2 in the previous days trading.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Companys product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. Its approved products are Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States, the European Union and subsequently in several other countries. Naglazyme received marketing approval in the United States, the European Union and subsequently in other countries. Kuvan was granted marketing approval in the United States, the European Union. Aldurazyme, which was developed in collaboration with Genzyme Corporation (Genzyme), was approved for marketing in the United States, the European Union, and subsequently in other countries. Firdapse was approved by the European Medicines Agency (EMA).